# Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/responding-to-fda-form-483-observations-at-the-conclusion-of-a-drug-cgmp-inspection/616a1c25-5ddb-4458-88d6-d59f11231a76

> FDA guidance document: Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection. Issue date: March 06, 2026. Get complete insights and analysis.

---

## Details

- Title: Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2026-03-06
- Last Changed: 2026-03-06
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2025-D-1504">FDA-2025-D-1504</a>

## Related Documents

- [Considerations in Demonstrating Interchangeability With a Reference Product: Update](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-in-demonstrating-interchangeability-with-a-reference-product-update/f154845a-a15e-4508-a634-dd22f907a286)
- [Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities](https://www.globalkeysolutions.net/guidances/guidance-document/remote-interactive-evaluations-of-drug-manufacturing-and-bioresearch-monitoring-facilities/b3f969a3-6d17-4b51-aee6-e6cb19f8e4ba)
- [Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff](https://www.globalkeysolutions.net/guidances/guidance-document/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/c198796d-4230-4499-a6ee-2f84eed424c9)